Inhibition of SARS-CoV replication by siRNA

Antiviral Res. 2005 Jan;65(1):45-8. doi: 10.1016/j.antiviral.2004.09.005.

Abstract

Serious outbreaks of severe acute respiratory syndrome (SARS), caused by the newly discovered coronavirus SARS-CoV, occurred between late 2002 and early 2003 and there is an urgent need for effective antiviral agents. RNA interference in animals and post-transcriptional gene silencing plants is mediated by small double-stranded RNA molecules named small interfering RNA (siRNA). Recently, siRNA-induced RNA interference(RNAi) may provide a new approach to therapy for pathogenic viruses, e.g. HIV and HCV. In this study, the silencing potential of seven synthetic siRNAs against SARS-CoV leader, TRS, 3'-UTR and Spike coding sequence have been applied to explore the possibility for prevention of SARS-CoV infection. We demonstrate that siRNAs directed against Spike sequences and the 3'-UTR can inhibit the replication of SARS-CoV in Vero-E6 cells, and holds out promise for the development of an effective antiviral agent against SARS-CoV.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3' Untranslated Regions / genetics
  • 3' Untranslated Regions / metabolism
  • Animals
  • Chlorocebus aethiops
  • Humans
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / metabolism
  • RNA Interference*
  • RNA, Small Interfering / metabolism
  • RNA, Small Interfering / pharmacology*
  • Severe Acute Respiratory Syndrome / virology
  • Severe acute respiratory syndrome-related coronavirus / drug effects
  • Severe acute respiratory syndrome-related coronavirus / physiology*
  • Spike Glycoprotein, Coronavirus
  • Vero Cells
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / metabolism
  • Virus Replication / drug effects*

Substances

  • 3' Untranslated Regions
  • Membrane Glycoproteins
  • RNA, Small Interfering
  • Spike Glycoprotein, Coronavirus
  • Viral Envelope Proteins